Venous thromboembolism (VTE) is the third most common cause of vascular mortality
worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE). In this …

Purpose: Cell-free DNA (CFDNA) is elevated in sepsis and correlates with mortality. This
DNA may come from nuclear, mitochondrial, or bacterial sources. Cell-free DNA from all three …

Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary
embolism, is a common and potentially preventable cause of morbidity and mortality. …

Background Due to a paucity of data on the efficacy and safety of direct oral anticoagulants (DOACs)
in patients with a body mass index >40 kg/m 2 or a weight >120 kg, the use of …

It is uncertain whether antiphospholipid antibodies (APAs) increase the risk of recurrence
after a first unprovoked venous thromboembolism (VTE). We tested for anticardiolipin …

Background Recent reports suggest an important contribution from frequent off-label use of
apixaban 2.5 mg twice daily to the higher rates of thromboembolic events observed in …

Background In patients with nonvalvular atrial fibrillation (AF), apixaban is given in doses of
5 or 2.5 mg twice daily, according to clinical characteristics. The usual on-treatment range of …

In patients with suspected venous thromboembolism, the goal is to accurately and rapidly
identify those with and without thrombosis. Failure to diagnose venous thromboembolism (VTE…

Peripheral artery disease (PAD) is associated with substantial morbidity, including a high
risk of cardiovascular and limb events and death. A growing body of evidence has …

Background Systematic reviews reporting time trends in mortality following major orthopaedic
surgery are few and have limitations. They reported on only a fraction (< 15%) of the …